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Abstract 
Cytoskeleton-free vesicles released from human red blood cells (RBC) transport exogenously supplied aminophospholipid analogues 
from the vesicle’s outer to inner leaflet at rates comparable to those of normal RBC (Beleznay et al. (1993) Biochemistry 32, 
3146-3152). Because polypelptides associated with the Rh blood group system have been implicated in the transbilayer movement of 
phosphatidylserine (PS), we investigated the relationship and co-localization of the aminophospholipid translocase and Rh in dilau- 
roylphosphatidylcholine-induced RBC vesicles. The transbilayer movement of fluorescent (NBD-PS) and photoactivatable (‘251-Na-PS) 
PS in RBC vesicles was ATE’- and temperature-dependent. Inhibition of PS transport by sulfhydryl reagents could be accomplished by 
direct vesicle treatment or by treating RBC before vesiculation. In the case of diamide- and pyridyldithioethylamine-mediated inhibition, 
NBD-PS transport could be restored by reduction with dithiothreitol, indicating that the movement of the PS transporter into the emerging 
vesicle was independent of the oxidative status of membrane sulfhydryls. The presence of Rh polypeptides in the vesicles was verified by 
direct immunoprecipitation of isotopically-labeled Rh and semi-quantified by antibody adsorption assays. Similar to the movement of the 
PS transporter, localization of Rh polypeptides in the vesicle membrane was independent of the red cell’s oxidative status. These results 
show that the PS translocase and Rh-related proteins colocalize in RBC vesicles suggesting that these proteins may be members of a 
multicomponent complex that plays a role in lipid movement and the generation of membrane lipid asymmetry. 
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1. Introduction 
The phospholipids of the human erythrocyte (RBC) are 
distributed asymmetrically across the cell’s membrane bi- 
layer. The choline-containing lipids predominate in the 
cell’s outer leaflet, whereas the aminophospholipids, phos- 
phatidylethanolamine and phosphatidylserine (PS), prefer- 
entially or exclusively localize in the cell’s inner leaflet. 
This distribution is, at least in part, controlled by the 
activity of an ATP-dependent aminophospholipid-specific 
transporter that shuttles lipids between membrane leaflets 
at different rates [1,2]. Thk activity, combined with other 
Abbreviations: BSA, bovine serum albumin; DLPC, dilauroylphos- 
phatidylcholine; D’IT, dithiothreitol; NBD-, 1-oleoyl-Z((N-(7-nitrobenz- 
2-oxa-1,3-diazol-4-yl)aminolcaproyl)-; NEM, N-ethylmaleimide; PC, 
phosphatidylcholine; PDA, pyridyldithioethylamine; PS, phosphatidyl- 
serine; RBC, human red blood cells. 
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lipid-membrane interactions, generates and maintains un- 
equal lipid distributions across the bilayer membrane [3,4]. 
Red cells can be induced to vesiculate by various 
techniques, including ATP depletion [5], calcium loading 
[6l, ageing [7,g], and the insertion of amphipaths into the 
cell’s outer leaflet [9-111. Irrespective of the method used, 
however, the vesicle’s protein and lipid composition al- 
ways resembles that of the red cell, with the exception of 
essentially complete exclusion of cytoskeletal components 
[12]. There are, however, differences in the relative amounts 
of specific proteins that remain with the remnant red cell 
and that localize in the vesicle membrane. Diffusion-re- 
stricted, cytoskeletal-linked membrane components, for ex- 
ample, do not segregate into the vesicle [13], whereas 
freely diffusible components preferentially segregate into 
the emerging vesicle. These include the mobile fraction of 
band 3 [13], glycophorin, complement receptor [14], and 
GPI-anchored proteins such as acetylcholine esterase [15], 
DAP [15], and CD59 [16]. 
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Although the lipid transporter has been biochemically 
and functionally well characterized, the protein responsible 
for the cell’s transport activity remains unidentified. Sev- 
eral studies suggest the involvement of 32 kDa Rh-associ- 
ated band 7 proteins 117-191, a 120 kDa Mg-ATPase 
[20,21], or a multimeric complex of the Mg-ATPase and 
an Rh-related polypeptide [22]. Because DMPC-induced 
vesicles transport PS [23] and Ca2+/EDTA/heat-induced 
vesicles have been reported to react with Rh(D) antibodies 
[24], this system provides a model for investigating the 
relationship between Rh and PS transport. In this study, we 
assessed the concomitant release of Rh polypeptides and 
the PS transporter into DLPC-induced vesicles [lo]. We 
found that both Rh polypeptides and PS transport activity 
colocalize in the emerging vesicle membrane. 
2. Materials and methods 
2.1. Materials and routine procedures 
DLPC and NBD-PC were purchased from Avanti Polar 
Lipids (Birmingham, AL). Carrier-free ‘251-N,-PC was 
synthesized from l-oleoyl-2-aminocaproyl-PC and azido- 
125 I(iodo)phenylf ro rionate p as previously described [25]. 
NBD-PS and ’ ‘I-N,-PS were prepared from NBD-PC 
and’251-N,-PC by phospholipase D-catalyzed base ex- 
change in the presence of L-serine as previously described 
[26]. PDA and ‘251-PDA were synthesized as previously 
described [18]. Diamide, NEM, and vanadate were ob- 
tained from Sigma. RBC were obtained from healthy 
volunteers by venipuncture into heparinized syringes. In 
some experiments, RBC were labeled with 51Cr ( u 1 mCi) 
for 30 min at 37” C; ‘251-PDA ( _ 0.1 mCi) for 20 min at 
0” C; or Na’25 I ( N 1 mCi) in the presence of four iodobeads 
(Pierce) for 20 min at 0” C. RBC ghost and vesicle proteins 
were analyzed by SDS-PAGE using 11% separating and 
6% stacking gels with the discontinuous buffer system of 
Laemmli [27]. The gels were stained, dried and autoradio- 
graphed with Kodak XAR-5 film or imaged on a Molecu- 
lar Dynamics PhosphorImager. Steady-state fluorescence 
of NBD-lipids was measured at 535 nm (A,, 468 nm) with 
a Farrand MKII spectrophotometer at room temperature 
using 10 nm slit widths. Radiation was monitored by 
scintillation counting using a Packard AutoGamma spec- 
trometer. 
2.2. Vesiculation 
Small unilamellar vesicles were prepared by sonication 
of DLPC (1.5 mM) in Hepes-saline buffer (144 mM NaCl, 
10 mM Hepes, 10 mM glucose, pH 7.3) followed by 
centrifugation at 30000 X g to remove metal fragments 
and large vesicles. Freshly drawn RBC were washed four 
times by centrifugation (2000 X g for 5 min) in Hepes- 
saline. The buffy coat was removed by aspiration. In most 
experiments cellular ATP levels were increased by incu- 
bating the cells in buffer A (100 mM NaH,PO,, 33 mM 
NaCl, 20 mM KCl, 1 mM MgCl,, 1 mM EGTA, 10 mM 
glucose, 10 mM pyruvate, 10 mM inosine, and 2 mM 
adenosine, pH 7.4) for 2 h at 37” C as described [23]. The 
RBC were then washed, resuspended in Hepes-saline to a 
10% hematocrit and incubated with DLPC (38 PM final 
concentration) at 4” C on an orbital shaker for the indicated 
period of time. Remnant RBC were removed by centrif- 
ugation at 850 X g for 5 min. This was repeated with the 
vesicle-containing supernatant to ensure complete RBC 
removal. Vesicles in the 850 X g supematant were concen- 
trated by centrifugation at 30 000 X g for 10 min. In early 
experiments, vesicles were purified by gel filtration chro- 
matography on Sephacryl S-1000 as described by Belez- 
nay et al. [23]. Other experiments indicated that this step 
was unnecessary and that the vesicles could be washed in 
Hepes-saline with identical results. Vesicle formation was 
monitored by scintillation counting of vesicles released 
from ‘251-PDA- and 5’Cr-labeled RBC or by acetylcholin- 
esterase activity. 
2.3. Electron microscopy 
Purified RBC vesicles were pelleted and fixed with 2% 
paraformaldehyde/3% glutaraldehyde in 0.1 M cacodylate 
buffer for 1 h at 4” C and post-fixed with 1% 0~0,. 
Samples for transmission electron microscopy (TEM) were 
stained with 1% uranylacetate, dehydrated in graded EtOH 
and embedded in Spurr resin. For scanning electron mi- 
croscopy (SEM), the samples were air-dried and sputtered 
with Pt/Pd following procedures developed for the pres- 
ervation of lipid vesicles [28]. 
2.4. Translocation of lipid analogues 
Lipid transport in RBC and in vesicles was monitored 
by back-exchange with BSA. Briefly, RBC (2. log/ml) or 
vesicles (from 1 ml packed RBC resuspended to 1 ml) 
were resuspended in Hepes-saline, mixed with NBD-lipids 
in ethanol (1 pg lipid/l0 ~1 of EtOH/ml) and incubated 
at 37” C. Aliquots (100 ~1) were removed at the indicated 
times and mixed with 1 ml of 1% BSA to remove lipid 
that was not transported to the cells’ or vesicles’ inner 
leaflet. The suspension was centrifuged for 5 min at 2000 
X g (RBC) or 20000 X g (vesicles) and the pellets were 
solubilized in 1% Triton X-100. The fraction of lipid 
transported was determined by fluorescence measurements 
of the amount of total vesicle-associated lipid (fluores- 
cence of vesicles centrifuged through Hepes-saline) and 
fluorescence remaining in the vesicles after BSA back-ex- 
change. 
Transport of azide-labeled lipids was carried out in the 
same manner except that the experiments were done under 
a red safelight and 5% BSA was used for back-exchange. 
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Fig. 1. Scanning and transmission electron microscopy of DLPC-induced vesiculation. Scanning (A) and transmission (B) EM of vesiculating red cells 
after 20 min incubation at 4” C in the presence of 38 PM DLPC. Scanning (Cl and transmission (D) EM of purified DLPC-induced RBC vesicles. Bar = 1 
pm except in (D) where bar = 0.1 pm. 
2.5. Azide-lipid labeling 
Washed RBC (2 * 10’ cells/ml) were incubated with 
1251-N,-PC or ‘251-N,-PS for 20 min at 37” C and washed 
with Hepes-saline. In some experiments, labeled cells were 
vesiculated with DLPC and the purified RBC vesicles 
were irradiated for 3 min (12 cm from an Osram HBO 
lOOW/2 super-pressure mercury lamp). In other experi- 
ments, the labeled cells were irradiated, washed, and then 
vesiculated. 
2.6. Immunoprecipitation 
RBC of known Rh phenotype (R,R,, [DCe/DCe]; rr, 
[cde/cde]) were prelabeled with ‘251-PDA or Na’251 and 
then vesiculated with DLPC as described above. In the 
case of ‘251-N,-PS labeling, RBC bearing cde/cde poly- 
peptides were labeled and vesiculated in the dark. The 
resulting vesicles were then irradiated as described above. 
Membrane vesicles obtained from 1 ml of packed RBC 
were resuspended in 400 ~1 of phosphate-buffered saline 
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Fig. 2. Release of DLPC-induced membrane vesicles from RBC. (A) Isotopically-labeled RBC (10% packed) were incubated at 4” C with 38 PM sonicated 
DLPC. At the indicated intervals, the fraction of radiation present in 8.50 X g supematants was determined by scintillation counting. (ml, “Cr; (01, 
1251-PDA. (B) Release of acetylcholinesterase activity from RBC incubated with 38 PM DLPC as described for panel A except that the cells were 
pretreated with the indicated inhibitors as described in Materials and methods. The release of acetylcholinesterase, expressed as the percent of maximum 
release, represents approx. 35% of the total cell-associated acetylcholinesterase activity. (+ 1, control cells; (01, PDA, (V ), vanadate; ( ??1, diamide; ( A 1, 
NEM. 
150 E.M. Bruckheimer et al./Biochimica et Biophysics Acta 1235 (1995) 147-154 
(PBS) and incubated overnight at 4” C with lo-25 pg of 
monoclonal antibody. Excess antibody was removed by 
washing, and the vesicles were solubilized in 300 ~1 of 
PBS containing 3% Triton X-100 for 1 h at 4” C. Insoluble 
material was removed by centrifugation at 20000 X g for 
30 min. Immune complexes in the supematant were then 
isolated with protein-A Sepharose (Sigma) as described 
previously [25]. The Sepharose-bound immunoprecipitated 
protein was released by heating in 1% SDS and analyzed 
by autoradiography after SDS-PAGE. 
2.7. Hemagglutination 
The direct hemagglutination titer of Rh antibodies and 
vesicle-adsorbed Rh antibodies were tested on papain- 
treated heterozygous (R,r) RBC. RBC vesicles were pre- 
pared from the red cells of homozygous Rh(D) (R,R,) and 
homozygous Rh(c) (rr) donors. These vesicles were puri- 
fied as described above and incubated with polyclonal 
anti-D or anti-c antibodies for 1 h at room temperature 
followed by an additional 30 min at 0” C. The vesicle-anti- 
body mixture was centrifuged at 20000 X g for 15 min at 
4” C. The antibody-containing supematant was removed 
and titered using standard protocols. 
3. Results 
3.1. Release of DLPC-induced membrane vesicles 
Because aminophospholipid translocase-mediated PS 
movement across the red cell membrane is critically de- 
pendent on cellular ATP levels, RBC were vesiculated at 
4” C to minimize nucleotide consumption. Freshly drawn 
RBC were labeled with 5’Cr or ‘*‘I-PDA and incubated 
with DLPC (38 PM) for 1 h at 4” C. Similar to vesicula- 
tion obtained with DMPC at 30-37“ C [9], RBC incubated 
with DLPC at 4” C underwent dramatic discocyte-to- 
echinocyte shape changes which most likely resulted in the 
release of vesicles from the tips of the membrane projec- 
tions (Fig. 1A and B). The time-course of vesiculation was 
assessed by measuring the amount of isotopically labeled 
proteins (Fig. 2A) and acetylcholinesterase (Fig. 2B) re- 
leased from the cells into the supematant. RBC vesicles 
first appeared in the supematant after an initial lag period 
of about 10 min and was complete within 45 min. Morpho- 
logical examination of vesicles obtained after removal of 
remnant RBC by centrifugation at 850 X g revealed rela- 
tively uniform hemoglobin-containing and empty spherical 
structures with an average diameter of 0.15 pm (Fig. 1C 
and D). The empty spheres are most likely unsealed vesi- 
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Fig. 3. Transport of NBD-PS in remnant cells and in vesicles generated from inhibitor-treated RBC. RBC were pretreated with the indicated inhibitors as 
described in Materials and methods and then vesiculated with DLPC. The suspension was centrifuged at 850 X g and the vesicle containing supematant 
was separated from the remnant cell pellet. The remnant cells and vesicles were then washed and their ability to transport NBD-PS (solid lines) and 
NBD-PC (dashed lines) was determined in the absence or presence of 10 mM DlT. ( + ), control cells; (01, PDA, ( v 1, vanadate; (W 1, diamide; (A 1, 
NEM. 
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cles, the fraction of which varied between 20-40% of the 
total vesicle population. Because these vesicles do not 
contain ATP, their presence is without affect on the uptake 
studies shown below. 
To determine if known inhibitors of aminophospholipid 
transport affect the ability of the cells to vesiculate, vesicle 
release from RBC pretreated with PDA, NEM, diamide, 
and vanadate was assessed. Fig. 2B shows essentially 
identical kinetics and similar quantities of membrane re- 
leased from control and inhibitor-treated cells. This indi- 
cates that DLPC-induced vesiculation proceeded in a man- 
ner that was independent of ATP and the oxidative status 
of membrane proteins. 
3.2. Transport of labeled PS analogues in RBC vesicles 
and remnant cells 
Fig. 3 shows that remnant RBC (Fig. 3A) and RBC 
vesicles (Fig. 3B) transported NBD-labeled PS but not PC. 
Similar to normal RBC, vesicles and remnant cells ob- 
tained from RBC pretreated with various inhibitors of 
aminophospholipid transport did not transport PS. It can be 
seen that PDA, diamide, NEM, and vanadate abrogated 
transport in the remnant cells and in the vesicles (Fig. 3A 
and B), and that inhibition of PS transport by the disulfide 
exchange reagents was mversible upon treatment with 
DTT (Fig. 3C and D). These data suggest that the move- 
ment of the aminophospholipid transporter into the bud- 
ding vesicle was unaffeci.ed by oxidation of membrane 
sulfhydryls. Transport inhibition by vanadate in remnant 
cells and in vesicles required higher concentrations (3 
mM> than that of normal cells (0.1 mM). This was proba- 
bly due to increased ATP levels in the remnant cells that 
were preincubated with buffer A (5-g-fold higher than 
normal levels) and to the poor uptake of solutes into the 
vesicle membrane. 
Inhibition of PS transport in the vesicles was not depen- 
dent on pretreatment of the donor RBC with inhibitors. 
Fig. 4 shows that vesicles derived from untreated RBC 
were sensitive to the same inhibitors and, in the case of 
PDA and diamide, inhibition was reversible with DTT. 
Essentially identical results were obtained in experiments 
employing 1251-N,-PS (results not shown). These data indi- 
cate that all of the components required for aminophospho- 
lipid-specific transport partitioned from the red cell mem- 
brane into the budding vesicle membrane. 
3.3. Protein analysis of R13C vesicle proteins 
SDS-PAGE analysis of Coomassie blue-stained ghost 
membranes and DLPC-induced vesicles derived from the 
same cells showed that the major cytoskeletal proteins 
were absent in the vesicles, and that band 3 and 32 kDa 
band 7 proteins were the two major membrane proteins 
released under these conditions (Fig. 5B). Semi-quantita- 
tive scanning densitometry of the Coomassie-stained gels 
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Fig. 4. Effect of inhibitors on the transport of NBD-PS in vesicles. 
Vesicles were generated from normal RBC as described in Materials and 
methods. Aliquots were then treated with inhibitors as described, washed, 
and their ability to transport NBD-PS in the absence (A) or presence (B) 
of D’IT was determined. ( + ), control vesicles; (a), vesicles treated with 
PDA, (v ), vanadate; ( ??), diamide; (A ), NEM. 
indicated that the band 7 proteins were relatively enriched 
in the vesicles and comprised about 14% of the vesicle 
membrane’s protein compared to about 4% of the ghost 
membrane’s protein (Fig. 5A). Analysis of these gels by 
autoradiography revealed, however, that in addition to 
iodine-labeled 32 kDa protein, several other proteins were 
released from the red cells into the vesicle membrane. For 
example, labeling with ‘*?PDA revealed that a substantial 
fraction of a diffusely labeled band in the range of 62-76 
kDa was released from the red cells (Fig. X, lane 1) into 
the vesicles (Fig. 5C, lane 3). Similarly, a 92 kDa protein 
(Fig. 5C, lane 41, probably glycophorin A dimer, was 
released from ‘**I-labeled RBC (Fi 
4. 
5C, lane 2). 
Analysis of the distribution of ’ ‘I-N,-PS in irradiated 
vesicles showed crosslinking of the probe to 32 kDa band 
7 polypeptides in vesicles derived from RBC containing 
increased (preincubated in buffer A) and normal ATP 
levels (Fig. 6, lanes 1 and 3, respectively). The fraction of 
probe crosslinked to 32 kDa polypeptides was decreased in 
vesicles derived from RBC pretreated with the transport 
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inhibitors, PDA (lane 4) and vanadate (lane 5) to levels 
obtained with nontransportable ‘251-N,-PC (lane 2). 
Because Rh polypeptides are a component of the band 7 
proteins and have been implicated in lipid transport, the 
presence of these polypeptides in the vesicles was deter- 
mined by immunoprecipitation with monoclonal antibod- 
ies. Fig. 5D and Fig. 6B show that iodine-labeled Rh was 
immunoprecipitable from ‘251-PDA-, 1251-, and 1251-N3- 
PS-labeled vesicles. Immunoprecipitation was specific be- 
cause monoclonal anti-D failed to precipitate protein from 
vesicles generated from these cells (not shown). 
Fig. 5. SDS-PAGE analysis of DLPC-induced vesicles and immuno- 
precipitation of labeled Rh polypeptide with Rh antibody. RBC (rr cells) 
prelabeled with “‘1-PDA or with “‘1 were vesiculated with DLPC and 
electrophoresed directly (B and Cl or after immunoprecipitation with Rh 
(anti-c) antibodies (D). (A) shows densitometric scans of Coomassie 
blue-stained RBC ghosts and DLPC-induced vesicles from panel B (lane 
1, ghosts; lane 2, vesicles). Panel C is an autoradiograph of ghosts (lanes 
1 and 2) and vesicles (lanes 3 and 4) labeled with 1251-PDA (1,3) or 
Na’*‘I (2,4). In Panel D, lanes 1 and 2 contain an immunoprecipitate of 
the same vesicles shown in panel C, lanes 3 and 4, respectively. Arrows 
mark the positions of molecular weight standards (97.4, 69, 46, 30, 21.5 
and 14.3 kDa). 
Fig. 6. Analysis of ‘251-N,-lipid labeled vesicles by SDS-PAGE. Control 
and inhibitor-treated RBC (rr) were vesiculated with DLPC. The purified 
vesicles were then incubated with 1251-N,-PS or ‘*‘I-N,-PC in the dark at 
37” C for 1 h, irradiated and analyzed by SDS-PAGE (A). Autoradiog- 
raphy of vesicles labeled with ‘*‘I-N,-PS were generated from RBC 
containing high ATP levels (lane 11, normal ATP levels (lane 31, PDA- 
(lane 4) and vanadate-treated RBC (lane 5). Lane 2 shows control 
vesicles incubated with “‘1-Ns-PC. (B) shows monoclonal anti-c 
immunoprecipitated Rh from vesicles generated from 1251-N,-PS labeled 
RBC. Arrows mark the positions of molecular weight standards (see Fig. 
51. 
3.4. Association of Rh polypeptides with the aminophos- 
pholipid transporter 
The data presented to this point indicate that both Rh 
polypeptides and the aminophospholipid transporter dis- 
tribute from the cell into the emerging vesicle upon 
DLPC-induced vesiculation. It also appears that 
labeling/inhibition of the aminophospholipid transporter 
with transport inhibitors did not affect the movement of 
the transporter into the budding vesicle. This is concluded 
from data showing that vesicles generated from diamide- 
or PDA-inhibited RBC can transport PS upon the addition 
of DTT. 
To verify that these inhibitors did not affect the local- 
ization of Rh polypeptides in the vesicle membrane, a 
series of semi-quantitative hemagglutination inhibition ex- 
periments were carried out (Table 1). Rh(c) and Rh(D) 
antibodies were adsorbed with vesicles generated from 
Rh(c) (rr cells)- and Rh(D)-expressing (R,R, cells) RBC 
Table 1 
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Presence of Rh polypeptides in vesicles derived from inhibitor-treated RBC a 
Phenotype RBC treatment 
unadsorbed antibody 
rr vesicles Ue/cde) control 
PDA 
NEM 
diamide 
R,R, vesicles (DCe/DCe) control 
PDA 
NEM 
diamide 
Hemagglutination titer 
anti-Rh(c) 
Y1 
27 
;: 
2’ 
Y1 
- 
- 
- 
anti-Rh(D) 
212 
212 
- 
- 
26 
26 
a RBC were treated with the indicated inhibitors as described in Materials and methods. Vesicles were generated from 2 ml of packed inhibitor-treated 
RBC. The vesicles were purified by sequential centrifugation and pelleted at 30 000 X g. Antibody adsorption was done by incubating polyclonal anti-c or 
anti-D with the vesicles for 1 h at 20” C followed bv 30 min at 0” C. Antibodv titers were then determined on papain-treated R,r (DCe/cde) cells which 
express both the c and D alleles. Hemagglutination is expressed as log, titers. 
after treatment with the various inhibitors. Preincubation of 
antibody with DLPC-induced vesicles from control (un- 
treated) RBC resulted in specific antibody adsorption. This 
can be seen by the approx. 30-fold reduction in titer after 
adsorption of the antibody with vesicles derived from RBC 
of the appropriate phenotype (Table 1). Thus, only anti-c 
was adsorbed by c-expressing rr vesicles (cde/cde) be- 
cause these vesicles do not express the D allele. Likewise, 
only anti-D was adsorbed by D-expressing R,R, vesicles 
(DCe/DCe) because these vesicles do not express the c 
epitope. Similar reductions in antibody titers were ob- 
served after adsorption on DLPC-induced vesicles derived 
from PDA-, NEM-, or diamide-treated RBC indicating that 
these inhibitors had no effect on the distribution of Rh 
polypeptides into the vesicle membrane. 
4. Discussion 
It is well established that membrane phospholipids of 
eukaryotic cells are not randomly distributed across the 
plasma membrane, but certain species and lipids of spe- 
cific molecular composition are distributed asymmetrically 
across the membrane bilayer [29]. This is especially evi- 
dent for the aminophospholipids, which preferentially re- 
side in the plasma membrane’s inner leaflet. Although it is 
still uncertain whether an active process is required to 
maintain lipid asymmetry, it is clear that an energy-depen- 
dent aminophospholipid translocase is responsible for the 
movement of aminopho?pholipids across the membrane 
and generates unequal transmembrane lipid distributions 
[3,41. 
Although considerable progress has been made in un- 
derstanding the molecular requirements of aminophospho- 
lipid movement in RBC, the proteins responsible for trans- 
port have not been unequivocally identified. The available 
data are, however, compatible with at least two proteins. 
Based on PS and sulfhydryl labeling studies, we have 
identified a 32 kDa protein that may be part of the Rh 
complex [2,25]. Using vanadate sensitivity and PS-stimu- 
lated ATPase activity, Devaux and colleagues have identi- 
fied a 120 kDa Mg-ATPase with characteristics compatible 
to those known for the aminophospholipid translocase 
[20,21]. Although these proteins are distinct, they are not 
mutually exclusive; both may be members of a more 
complex structure that requires the participation of several 
proteins. Indeed, purification of a 120 kDa candidate 
aminophospholipid-transporting Mg-ATPase copurified 
with substantial amounts of 32 kDa band 7 proteins [30]. 
Because RBC vesicles contain a limited number of red 
cell proteins yet still transport exogenously supplied PS 
analogs [231, we used this system as a model to investigate 
the relationship between PS transport and Rh polypeptides. 
Although red cells can be induced to vesiculate by a 
variety of techniques, the protein composition of the vesi- 
cle membrane seems to be independent of the mechanism 
responsible for its formation. SDS-PAGE analysis of mem- 
brane-derived vesicles invariably shows an absence of 
cytoskeletal proteins and varying amounts of other mem- 
brane components, including what appear to be dispropor- 
tionate amounts of proteins in the band 3 and band 7 
regions [6,7,31]. The results shown here demonstrate that 
Rh polypeptides and the aminophospholipid transporter 
segregate into budding RBC vesicles generated upon incu- 
bation of the cells with DLPC. This was concluded from 
experiments showing that, (1) Rh antibody specifically 
immunoprecipitated Rh polypeptides from vesicles, (2) 
vesicles can specifically adsorb Rh antibodies, and (3) 
vesicles can transport PS. Because the restricted diffusion 
of cytoskeleton-linked integral membrane proteins pre- 
vents their segregation into emerging vesicles [13], these 
experiments suggest that at least a fraction of cell’s Rh 
polypeptides and aminophospholipid transporter are not 
associated with the membrane cytoskeleton. 
PS transport was ATP- and temperature-dependent, and 
dependent on the oxidative state of membrane sulfhydryls 
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in the initial red cell population as well as in the mem- 
brane vesicles. This was concluded from the experiments 
shown in Fig. 3, in which remnant RBC and vesicles 
generated from inhibitor-treated or ATP-depleted red cells 
did not transport PS. Similarly, transport was blocked 
when vesicles derived from control RBC were treated with 
the same inhibitors (Fig. 4). In both cases, inhibition by the 
disulfide exchange reagents was reversible upon reduction 
with DTT (Figs. 3 and 4). 
[2] Connor, J., Pak, C.H., Zwaal, R.F.A. and Schroit, A.J. (1992) J. 
Biol. Chem. 267, 19412-19417. 
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